Last $0.12 USD
Change Today +0.0009 / 0.74%
Volume 5.3K
RGRX On Other Exchanges
As of 8:10 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

regenerx biopharmaceuticals (RGRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - $0.28
52 Week Low
12/30/13 - $0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

regenerx biopharmaceuticals (RGRX) Related Businessweek News

No Related Businessweek News Found

regenerx biopharmaceuticals (RGRX) Details

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of molecules for tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tß4), an amino acid peptide. It develops RGN-259, a topical eye drops that that has completed the Phase IIa exploratory clinical trials and for the regeneration of corneal tissues damaged by injury, disease, or other pathology; and RGN-352, an injectable formulation, which has completed Phase I clinical trials and is intended to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications treated by systemic administration. The company also develops RGN-137, a topical gel that is in Phase II clinical trials and intended for the treatment of epidermolysis bullosa, pressure ulcers, and venous stasis ulcers. It also seeks to identify and evaluate Tß4 peptide fragments and derivatives for use as components in cosmeceutical and consumer products. RegeneRx Biopharmaceuticals, Inc. has a strategic partnership with Defiante Farmaceutica S.A. for the development and marketing of RGN-137 and RGN-352 for specified indications in Europe and other countries. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

regenerx biopharmaceuticals (RGRX) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $65.0K
Vice President of Clinical & Regulatory Affai...
Total Annual Compensation: $97.2K
Compensation as of Fiscal Year 2013.

regenerx biopharmaceuticals (RGRX) Key Developments

Regenerx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd. Announce Chinese FDA Approval of Phase II IND for RGN-259

RegeneRx Biopharmaceuticals Inc. and Lee's Pharmaceutical Holdings Ltd. jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China. On 17 June 2014, Lee's received the official CFDA Acceptance Notice (No. CXHL1400799X) for its application to conduct the Phase II trial, which aims to assess the safety and efficacy of RGN-259. There is clearly an unmet medical need in this area. RegeneRx demonstrated in its Phase II study that RGN-259 is a promising agent in alleviating dry eye syndrome by addressing the underlying pathology with a unique mechanism of action.

Regenerx Biopharmaceuticals Inc. announced delayed annual 10-K filing

On 04/01/2014, Regenerx Biopharmaceuticals Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

RegeneRx Biopharmaceuticals Wins USD 1.35 Million Under Product License and Securities Purchase Agreement

RegeneRx Biopharmaceuticals announced the receipt of the initial USD 1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co. Under the agreement, G-treeBNT will develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan and Macau). In addition, G-treeBNT will develop RegeneRx's RGN-137 topical dermal gel product candidate in the US. As part of the agreement, G-treeBNT purchased stock at USD 0.12 per share, will make an additional equity investment of USD 1.0 million at USD 0.12 per share by August 31, 2014 as well as retain an option until January 31, 2015 to purchase additional common stock for USD 825,000 at USD 0.15 per share.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGRX:US $0.12 USD +0.0009

RGRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RGRX Industry Range
No financial data is available for RGRX.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERX BIOPHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at